Takeda's subcutaneous formulation of Entyvio smashes primary endpoint in Crohn's disease

Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gutselective biologic Entyvio vedolizumab showing that the therapy met its primary endpoint as a maintenance treatment for moderately to severely active Crohn's disease CD.The data ...